Experimental drug improves psychosis in Parkinson's disease

10/31/2013 | HealthDay News

Data on 199 Parkinson's patients with disease-related psychosis showed those who took Acadia Pharmaceuticals' experimental drug pimavanserin attained significant improvements in psychotic symptoms at 43 days compared with the placebo arm. "Pimavanserin is not yet licensed, but could potentially offer a change in the treatment of these distressing and impactful symptoms," lead researcher Dr. Clive Ballard stated in The Lancet.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL